UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 227

Sortiert nach

Anticancer Cytokines: Biology and Clinical Effects of Interferon-α2, Interleukin (IL)-2, IL-15, IL-21, and IL-12

Seminars in oncology, 2015-08, Vol.42 (4), p.539-548

2015

Link zum Volltext

Verfügbarkeit prüfen

Immune-Mediated Adverse Events Associated with Ipilimumab CTLA-4 Blockade Therapy: The Underlying Mechanisms and Clinical Management

Scientifica (Cairo), 2013-01, Vol.2013, p.857519-19

2013

Link zum Volltext

Verfügbarkeit prüfen

Immunotherapy of cancer in 2012

CA: a cancer journal for clinicians, 2012-09, Vol.62 (5), p.309-335

2012

Link zum Volltext

Verfügbarkeit prüfen

Avoiding Severe Toxicity From Combined BRAF Inhibitor and Radiation Treatment: Consensus Guidelines from the Eastern Cooperative Oncology Group (ECOG)

International journal of radiation oncology, biology, physics, 2016-06, Vol.95 (2), p.632-646

2016

Link zum Volltext

Verfügbarkeit prüfen

Update on adjuvant therapy in late-stage resected melanoma

Clinical advances in hematology & oncology, 2021-12, Vol.19 (12), p.753

Tarhini, Ahmad A

2021

Link zum Volltext

Verfügbarkeit prüfen

IFN-α in the treatment of melanoma

The Journal of immunology (1950), 2012-10, Vol.189 (8), p.3789-3793

2012

Link zum Volltext

Verfügbarkeit prüfen

Single-cell Characterization of the Cellular Landscape of Acral Melanoma Identifies Novel Targets for Immunotherapy

Clinical cancer research, 2022-05, Vol.28 (10), p.2131-2146

2022

Link zum Volltext

Verfügbarkeit prüfen

Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF -Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134

Journal of clinical oncology, 2023-01, Vol.41 (2), p.186-197

2023

Link zum Volltext

Verfügbarkeit prüfen

Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609

Journal of clinical oncology, 2020-02, Vol.38 (6), p.567-575

2020

Link zum Volltext

Verfügbarkeit prüfen

Safety and Efficacy of Combination Immunotherapy With Interferon Alfa-2b and Tremelimumab in Patients With Stage IV Melanoma

Journal of clinical oncology, 2012-01, Vol.30 (3), p.322-328

2012

Link zum Volltext

Verfügbarkeit prüfen

CTLA-4 blockade and interferon-α induce proinflammatory transcriptional changes in the tumor immune landscape that correlate with pathologic response in melanoma

PloS one, 2021-01, Vol.16 (1), p.e0245287-e0245287

2021

Link zum Volltext

Verfügbarkeit prüfen

Immune Checkpoint Blockade and Interferon-α in Melanoma

Seminars in oncology, 2015-06, Vol.42 (3), p.436-447

2015

Link zum Volltext

Verfügbarkeit prüfen

PD-1 and Tim-3 Regulate the Expansion of Tumor Antigen-Specific CD8+ T Cells Induced by Melanoma Vaccines

Cancer research (Chicago, Ill.), 2014-02, Vol.74 (4), p.1045-1055

2014

Link zum Volltext

Verfügbarkeit prüfen

Treatment-Free Survival: A Novel Outcome Measure of the Effects of Immune Checkpoint Inhibition-A Pooled Analysis of Patients With Advanced Melanoma

Journal of clinical oncology, 2019-12, Vol.37 (35), p.3350-3358

2019

Link zum Volltext

Verfügbarkeit prüfen

Cost-Effective Patient Selection for Adjuvant Therapy in Stage IIIA Melanoma

Journal of the American College of Surgeons, 2020-11, Vol.231 (5), p.554-556

2020

Link zum Volltext

Verfügbarkeit prüfen

Next Generation of Immunotherapy for Melanoma

Journal of clinical oncology, 2008-07, Vol.26 (20), p.3445-3455

2008

Link zum Volltext

Verfügbarkeit prüfen

Randomized, Placebo-Controlled, Phase III Trial of Yeast-Derived Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus Peptide Vaccination Versus GM-CSF Plus Peptide Vaccination Versus Placebo in Patients With No Evidence of Disease After Complete Surgical Resection of Locally Advanced and/or Stage IV Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E4697)

Journal of clinical oncology, 2015-12, Vol.33 (34), p.4066-4076

2015

Link zum Volltext

Verfügbarkeit prüfen

The impact of CTLA-4 blockade and interferon-α on clonality of T-cell repertoire in the tumor microenvironment and peripheral blood of metastatic melanoma patients

Oncoimmunology, 2019-11, Vol.8 (11), p.e1652538-e1652538

2019

Link zum Volltext

Verfügbarkeit prüfen

Phase Ib/II Study of Pembrolizumab and Pegylated-Interferon Alfa-2b in Advanced Melanoma

Journal of clinical oncology, 2018-12, Vol.36 (35), p.JCO1800632-3458

2018

Link zum Volltext

Verfügbarkeit prüfen

Sensitivity of treatment-free survival to subgroup analyses in patients with advanced melanoma treated with immune checkpoint inhibitors

Melanoma research, 2022-02, Vol.32 (1), p.35

2022

Link zum Volltext

Verfügbarkeit prüfen

One-Anastomosis Gastric Bypass Revision for Gastroesophageal Reflux Disease: Long Versus Short Biliopancreatic Limb Roux-en-Y Gastric Bypass

Obesity surgery, 2022-04, Vol.32 (4), p.970-978

2022

Link zum Volltext

Verfügbarkeit prüfen

Phase II Study of Everolimus (RAD001) in Previously Treated Small Cell Lung Cancer

Clinical cancer research, 2010-12, Vol.16 (23), p.5900-5907

2010

Link zum Volltext

Verfügbarkeit prüfen

How much of a good thing? What duration for interferon alfa-2b adjuvant therapy?

Journal of clinical oncology, 2012-11, Vol.30 (31), p.3773-3776

2012

Link zum Volltext

Verfügbarkeit prüfen

Aflibercept (VEGF Trap) in Inoperable Stage III or Stage IV Melanoma of Cutaneous or Uveal Origin

Clinical cancer research, 2011-10, Vol.17 (20), p.6574-6581

2011

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 227

Suche als RSS-Feed

Aktive Filter

KollektionNature

ThemaMelanoma

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(212)
Mit Volltextzugriff
(216)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Anticancer Cytokines: Biology and Clinical Effects of Interferon-α2, Interleukin (IL)-2, IL-15, IL-21, and IL-12

Immune-Mediated Adverse Events Associated with Ipilimumab CTLA-4 Blockade Therapy: The Underlying Mechanisms and Clinical Management

Immunotherapy of cancer in 2012

Avoiding Severe Toxicity From Combined BRAF Inhibitor and Radiation Treatment: Consensus Guidelines from the Eastern Cooperative Oncology Group (ECOG)

Update on adjuvant therapy in late-stage resected melanoma

IFN-α in the treatment of melanoma

Single-cell Characterization of the Cellular Landscape of Acral Melanoma Identifies Novel Targets for Immunotherapy

Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF -Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134

Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609

Safety and Efficacy of Combination Immunotherapy With Interferon Alfa-2b and Tremelimumab in Patients With Stage IV Melanoma

CTLA-4 blockade and interferon-α induce proinflammatory transcriptional changes in the tumor immune landscape that correlate with pathologic response in melanoma

Immune Checkpoint Blockade and Interferon-α in Melanoma

PD-1 and Tim-3 Regulate the Expansion of Tumor Antigen-Specific CD8+ T Cells Induced by Melanoma Vaccines

Treatment-Free Survival: A Novel Outcome Measure of the Effects of Immune Checkpoint Inhibition-A Pooled Analysis of Patients With Advanced Melanoma

Cost-Effective Patient Selection for Adjuvant Therapy in Stage IIIA Melanoma

Next Generation of Immunotherapy for Melanoma

The impact of CTLA-4 blockade and interferon-α on clonality of T-cell repertoire in the tumor microenvironment and peripheral blood of metastatic melanoma patients

Phase Ib/II Study of Pembrolizumab and Pegylated-Interferon Alfa-2b in Advanced Melanoma

Sensitivity of treatment-free survival to subgroup analyses in patients with advanced melanoma treated with immune checkpoint inhibitors

One-Anastomosis Gastric Bypass Revision for Gastroesophageal Reflux Disease: Long Versus Short Biliopancreatic Limb Roux-en-Y Gastric Bypass

Phase II Study of Everolimus (RAD001) in Previously Treated Small Cell Lung Cancer

Jagged2 targeting in lung cancer activates anti-tumor immunity via Notch-induced functional reprogramming of tumor-associated macrophages

How much of a good thing? What duration for interferon alfa-2b adjuvant therapy?

Aflibercept (VEGF Trap) in Inoperable Stage III or Stage IV Melanoma of Cutaneous or Uveal Origin

Aktive Filter

Suchergebnisse filtern